Key result
Dual TRPC4/5 knockdown inhibits VSMC proliferation and calcium influx without affecting endothelial cells.
Why the study?
Drug-eluting stent agents inhibit both vascular smooth muscle cells and vascular endothelial cells, prompting a search for target molecules that inhibit VSMC proliferation without affecting VECs.
Does concurrent knockdown of TRPC4 and TRPC5 selectively inhibit the proliferation of human coronary artery vascular smooth muscle cells without affecting vascular endothelial cells?
Does concurrent knockdown of TRPC4 and TRPC5 selectively inhibit the proliferation of human coronary artery vascular smooth muscle cells without affecting vascular endothelial cells?
Concurrent inhibition of TRPC4 and TRPC5 selectively suppresses vascular smooth muscle cell proliferation while sparing endothelial cells, identifying a promising molecular target for next-generation drug-eluting stents that could reduce restenosis without delaying endothelial healing.
May support selective TRPC4/5 targeting to limit restenosis; leaves open human translation from animal data.
Aims: The main treatment for coronary heart disease is percutaneous coronary intervention (PCI), and drug-eluting stents are designed to inhibit vascular smooth muscle cell (VSMCs) proliferation and migration causing restenosis by releasing pharmacological agents into the vessel wall. Once drug-eluting stents are deployed, these pharmacological agents exert many biological effects in the coronary circulation, not only inhibition of VSMCs but also extension to vascular endothelial cells (VECs). The purpose of this study was to explore target molecules that inhibit VSMCs proliferation without affecting VECs. Methods: mRNA and protein expressions of transient receptor potential channels (TRPCs) in cultured VSMCs and VECs were determined by western blotting and RT-qPCR. VSMCs and VECs proliferation was evaluated using CCK-8 assays and western blotting of proliferating cell nuclear antigen (PCNA). Calcium backfilling assays were performed to detect intracellular calcium ion concentration in cultured VSMCs and VECs. Results: The TRPC6 expression was more abundant in VECs than VSMCs, while TRPC4 and TRPC5 expressions were more abundant in VSMCs than VECs. Knockdown of TRPC4 or TRPC5 alone had no remarkable inhibitory effect on VSMC proliferation. Synergistic knockdown of TRPC4 and TRPC5 inhibited the proliferation of VSMCs, declined the expression of the PCNA, and reduced the intracellular calcium ion concentration but not VECs. Conclusion: These data suggest that concurrent inhibition of TRPC4 and TRPC5 inhibits VSMCs proliferation without affecting VECs, thus providing novel targets for developing pharmacological agents for drug-eluting stents.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2021) studied In-stent restenosis / Vascular smooth muscle cell proliferation. Concurrent siRNA knockdown of TRPC4 and TRPC5 (siTRPC4 and siTRPC5) vs. Scramble siRNA negative control (NC) or single knockdown of TRPC4 or TRPC5 alone was evaluated on VSMC proliferation, proliferating cell nuclear antigen (PCNA) expression, and intracellular calcium ion concentration (p=<0.05). Synergistic siRNA knockdown of TRPC4 and TRPC5 significantly inhibited VSMC proliferation, PCNA expression (p<0.05), and intracellular calcium concentration (p<0.05) without affecting VECs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: